An Alzheimer's Drug Could Supercharge This High-Risk Stock. Is It Worth a Buy Here? [Yahoo! Finance]
vTv Therapeutics (NASDAQ:VTVT) is now covered by analysts at TD Cowen. They set a "buy" rating and a $67.00 price target on the stock.
vTv Therapeutics (NASDAQ:VTVT) is now covered by analysts at Cowen Inc. They set a "buy" rating on the stock.
vTv Therapeutics (NASDAQ:VTVT) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
vTv Therapeutics (NASDAQ:VTVT) was upgraded by analysts at
Wall Street Z